Contribution of Lung Cells in Allergic Asthma
The purpose of this study is to examine bronchial mucosal mast cells before, immediately after, and 2 months after a course of treatment with anti-immunoglobulin (Ig)E.
|Study Design:||Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
|Official Title:||Immune Dysregulation in Allergic Asthma|
- Bronchial mucosal mast cells (measured at Months 0 and 2) [ Time Frame: 5 years ] [ Designated as safety issue: No ]Asthmatics are administered Omalizumab and immunized with KLH
|Study Start Date:||December 2005|
|Study Completion Date:||January 2008|
|Primary Completion Date:||January 2008 (Final data collection date for primary outcome measure)|
Pulmonary mast cells are thought to be important in both acute asthma episodes and the pathogenesis of asthma. The study will use the recently released anti-IgE, which has been demonstrated to dramatically decrease IgE receptor expression on circulating basophils, as a probe to assess the contribution of pulmonary mast cells to asthma.
Well-characterized mild atopic asthmatics will be treated with anti-IgE. Allergen induced asthma, allergen skin tests, basophil IgE receptors, and pulmonary mucosal mast cells well be examined before, immediately after, and 2 months after treatment with anti-IgE.
|United States, New Mexico|
|University of New Mexico|
|Albuquerque, New Mexico, United States, 87131|
|Principal Investigator:||Mark Schuyler, MD||University of New Mexico|